The document provides a financial overview of the healthcare sector's performance, highlighting key metrics such as last price, high and low prices, volume, and SMA(15). It discusses the sector's outperformance compared to the S&P500 over the last four years, driven by factors like improving R&D returns, efficiency gains, and a supportive regulatory environment. The document also notes a significant drop in the Nasdaq Biotech Index due to congressional scrutiny over Gilead Sciences' pricing of its hepatitis C drug, Sovaldi.
doj/DataSet10/EFTA01453443.pdf
{"key_people":["Gilead Sciences"],"document_type":"tabular","document_subtype":"financial report","key_organizations":["Nasdaq Biotech Index","Gilead Sciences"],"reference_numbers":["DB-SDNY-0111025","SDNY_GM_00257209","EFTA01453443"]}